

FOR IMMEDIATE RELEASE

BIOLEX THERAPEUTICS TO PRESENT AT THE BIOCENTURY AND THOMSON FINANCIAL “FUTURE LEADERS IN THE BIOTECH INDUSTRY” CONFERENCE

PITTSBORO, NORTH CAROLINA, March 26, 2007 - Biolex Therapeutics today announced that it will be presenting at the Future Leaders in the Biotech Industry conference hosted by BioCentury and Thomson Financial on Thursday, March 29, 2007 at the Millennium Broadway Hotel in New York City. Biolex management will provide an update regarding recent and upcoming milestones, including the Locteron™ Phase 2 program in hepatitis C, the advancement of BLX-155, and programs associated with the optimization of monoclonal antibodies.

Specific details regarding Biolex’s presentation are as follows:

Conference: 14th Anniversary of Future Leaders in the Biotech Industry
Date: March 29, 2007
Time: 9:30 a.m. EDT with breakout session immediately following
Location: Millennium Broadway Hotel, 145 West 44th Street, New York, NY
Room: Presentation room 304/305, Breakout room 310

About Biolex Therapeutics

Biolex Therapeutics is developing and commercializing therapeutic proteins based on the LEX SystemSM, its patented expression system that enables the production of hard-to-make proteins and the optimization of monoclonal antibodies. The Company is developing a proprietary pipeline of products that rely upon known mechanisms of action to provide a reduced risk profile while targeting large, proven pharmaceutical markets. Biolex’s lead clinical candidate, Locteron™, is being developed as a best-in-class controlled-release interferon alfa for the treatment of hepatitis C. The Company’s second product candidate, BLX-155, is a direct-acting thrombolytic, designed to break up clots in certain diseases such as acute peripheral arterial disease, deep vein thrombosis and catheter occlusion. In addition, the unique capabilities of the LEX System have led to collaborations with Centocor, Medarex and other leading pharmaceutical/biotech companies. Biolex is a venture capital-backed company located in the Research Triangle region of North Carolina, United States. For additional information, please visit Biolex’s web site at www.biolex.com.

###

Contacts:

Media: Michelle Linn, Linnden Communications, 508-419-1555, linnmich@comcast.net.
Investors: Dale Sander, Chief Financial Officer, 858-663-6993, dsander@biolex.com

